Literature DB >> 12699744

Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo.

Kerry Zobel1, Michael F T Koehler, Maureen H Beresini, Lisa D Caris, Daniel Combs.   

Abstract

A series of phosphate ester based small molecules designed to bind tightly to serum albumin were applied to the amino terminus of an anticoagulant peptide in an effort to increase its protein binding in vivo. The tagged peptides exhibited high affinity for both rabbit and human serum albumin when passed through liquid chromatographic columns with serum albumins incorporated into the stationary phase. The peptides were then administered intravenously to rabbits and found to have a greater than 50-fold increase in plasma half life. The highest affinity peptides showed a reduction in bioactivity consistent with their sequestration away from their protein target in the presence of 0.1% rabbit serum albumin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699744     DOI: 10.1016/s0960-894x(03)00209-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.

Authors:  Alessandro Zorzi; Sara Linciano; Alessandro Angelini
Journal:  Medchemcomm       Date:  2019-06-06       Impact factor: 3.597

Review 2.  Derivatization with fatty acids in peptide and protein drug discovery.

Authors:  Peter Kurtzhals; Søren Østergaard; Erica Nishimura; Thomas Kjeldsen
Journal:  Nat Rev Drug Discov       Date:  2022-08-24       Impact factor: 112.288

3.  "Human and Mouse Cross-Reactive" Albumin-Binding Helix-Loop-Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins.

Authors:  Yuto Nakatani; Zhengmao Ye; Yuki Ishizue; Taishi Higashi; Teruko Imai; Ikuo Fujii; Masataka Michigami
Journal:  Mol Pharm       Date:  2022-05-28       Impact factor: 5.364

Review 4.  Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction.

Authors:  Wei Chen; Bryant C Yung; Zhiyong Qian; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

5.  Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.

Authors:  Yijun Huang; Edimara S Reis; Patrick J Knerr; Wilfred A van der Donk; Daniel Ricklin; John D Lambris
Journal:  ChemMedChem       Date:  2014-07-23       Impact factor: 3.466

Review 6.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors:  Zhibo Liu; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2016-03-07       Impact factor: 54.564

Review 7.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561

Review 8.  Peptide phage display as a tool for drug discovery: targeting membrane receptors.

Authors:  Peter Molek; Borut Strukelj; Tomaz Bratkovic
Journal:  Molecules       Date:  2011-01-21       Impact factor: 4.411

9.  A biomimetic approach for enhancing the in vivo half-life of peptides.

Authors:  Sravan C Penchala; Mark R Miller; Arindom Pal; Jin Dong; Nikhil R Madadi; Jinghang Xie; Hyun Joo; Jerry Tsai; Patrick Batoon; Vyacheslav Samoshin; Andreas Franz; Trever Cox; Jesse Miles; William K Chan; Miki S Park; Mamoun M Alhamadsheh
Journal:  Nat Chem Biol       Date:  2015-09-07       Impact factor: 15.040

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.